On August 6, 2025, Precision BioSciences, Inc. reported positive results from the Phase 1 ELIMINATE-B clinical trial evaluating PBGENE-HBV for hepatitis B, showing that it was well-tolerated in three patients with significant HBsAg reductions. All patients had no serious adverse events, and one patient maintained a durable HBsAg reduction of approximately 50%.